Welcome to the Annals of Transplantation

Annals of Transplantation is one of the fast-developing journals open to all scientists and fields of transplant medicine and related research. The journal is published quarterly and provides extensive coverage of the most important advances in transplantation.
Using an electronic on-line submission and peer review tracking system, Annals of Transplantation is committed to rapid review and publication. The average time... read more

Published: 2016-02-04

Early Initiation of Everolimus After Liver Transplantation: A Single-Center Experience

Uta Herden, Antonio Galante, Lutz Fischer, Sven Pischke, Jun Li, Eike Achilles, Martina Koch, Bjoern Nashan, Martina Sterneck

(Department of Hepatobiliary and Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany)

Ann Transplant 2016; 21:77-85

DOI: 10.12659/AOT.895800

BACKGROUND: Evidence relating to early everolimus use after liver transplantation remains limited.
MATERIAL AND METHODS: Ninety-one adult patients undergoing liver transplantation at our center during 2007–2012 in whom everolimus therapy was initiated <3 months post-transplant were analyzed retrospectively. Everolimus was started on days 1–5 in 50 patients (group 1) and after day 5 in 41 patients (group 2). Most patients continued to receive low-dose cyclosporine (59.3%, target 50–80 ng/ml) or low-dose tacrolimus (25.3%; target 3–5 ng/ml). Mean follow-up was 4.6 years.
RESULTS: One-, three- and five-year patient survival rates were 80.5%, 74.2%, and 70.5%, respectively, and did not differ between groups 1 and 2. Six patients (6.6%) developed biopsy-proven acute rejection after a median of 47 days (range 27–356 days). Everolimus was discontinued due to adverse events in 21 patients (23.1%). Incisional hernia repair occurred in 14.0% and 9.4% of patients in group 1 and 2, respectively. Renal function remained stable during follow-up, despite poor baseline function.
CONCLUSIONS: Everolimus with very low-dose calcineurin inhibitor given immediately after liver transplantation appears safe and effective, achieving a low rejection rate with well-preserved renal function.

Keywords: Cyclosporine, Immunosuppressive Agents, Liver Transplantation, Tacrolimus, Treatment Outcome

Related Articles (0)

Coming Soon...

Published: 2016-02-02

Magnetic Resonance Imaging in Diagnosis and Monitoring of Hepatocellular Carcinoma in Liver Transplantati...

Cesur Samanci, Fatemeh Sobhani, Enver Ucbilek, Katie Rakestraw, Nabil N. Dagher, Ihab R. Kamel, Ahmet Gurakar

Ann Transplant 2016; 21:68-76

DOI: 10.12659/AOT.895595

Published: 2016-01-31

Single Nucleotide Polymorphisms in MORC4, CD14, and TLR4 Are Related to Outcome of Allogeneic Stem Cell T...

Elisabeth Norén, Deepti Verma, Peter Söderkvist, Tilman Weisselberg, Jan Söderman, Kourosh Lotfi, Sven Almer

Ann Transplant 2016; 21:56-67

DOI: 10.12659/AOT.895389